The present disclosure relates to implant tools and techniques for implanting implantable medical leads or other implantable components in extravascular locations.
Implantable cardiac defibrillator (ICD) systems are used to deliver high energy electrical pulses or shocks to a patient's heart to terminate life threatening arrhythmias, such as ventricular fibrillation. Traditional ICD systems include a housing that encloses a pulse generator and other electronics of the ICD and is implanted subcutaneously in the chest of the patient. The ICD is connected to one or more implantable medical electrical leads that are implanted within the heart, referred to herein as transvenous leads.
Traditional ICD systems that utilize transvenous leads may not be the preferable ICD system for all patients. For example, some patients with difficult vascular access precludes placement of transvenous leads. As another example, children and other younger patients may also be candidates for non-transvenous ICD systems. Moreover, transvenous leads may become fibrosed in the heart over time, making lead revision and extraction procedures challenging.
An extravascular ICD system may be preferred for these patients. An extravascular ICD system includes a lead (or leads) that are implanted extravascularly in the patient, e.g., outside and/or exclusive of the heart. As such, the extravascular ICD may eliminate the need to implant transvenous leads within the heart. Instead, the lead(s) may be implanted subcutaneously, substernally, or in other extravascular locations.
This disclosure provides various embodiments of implant tools and implant techniques utilizing those tools. In one embodiment, an implant tool comprises a handle and a shaft. The shaft includes a proximal end adjacent the handle, a distal end, an open channel that extends from near the proximal end to the distal end, and at least one lumen that extends from a proximal end of the shaft to a location near the distal end of the shaft. The implant tool may also include a coupler configured to connect to a fluid delivery device. In one example, the fluid delivery device may be a syringe. In some instances, the handle of the implant tool may include a compartment or a recess configured to receive the fluid delivery device.
In another embodiment, an implant tool may include a handle and a shaft. The shaft includes a proximal end adjacent the handle, a distal end, a first open channel that extends from near the proximal end to the distal end, and a second open channel that extends from near the proximal end to a location near the distal end. The first open channel may have a width that is greater than or equal to an outer diameter of an implantable medical lead and the second open channel may be sized to receive a fluid delivery tube, a guide wire, a needle, a radiopaque tube/rod, an electrical probe or other structure. The implant tool may also include a fluid delivery tube within the second open channel.
In some instances, implant tool may further include a sheath configured to be placed on the shaft of the implant tool. The sheath includes a body having a proximal end and a distal end, a channel formed by the body, the channel extending from the proximal end to the distal end of the body, and an opening that extends along the body of the sheath from the proximal end to the distal end. In one example, the when the sheath is placed over the shaft of the implant tool, the first open channel of the shaft is accessible via the opening of the sheath and the body of the sheath holds the fluid delivery tube within the second open channel. In another example, when the sheath is placed over the shaft of the implant tool, a fluid delivery lumen is formed by the second open channel of the shaft and the body of the sheath. In a further example, the sheath may further include a tube integrated into the body of the sheath. The tube of the sheath may be configured to be placed within the second open channel of the shaft of the implant tool when the sheath is placed over the shaft.
This summary is intended to provide an overview of the subject matter described in this disclosure. It is not intended to provide an exclusive or exhaustive explanation of the apparatus and methods described in detail within the accompanying drawings and description below. Further details of one or more examples are set forth in the accompanying drawings and the description below.
ICD 14 may include a housing that forms a hermetic seal that protects components of ICD 14. The housing of ICD 14 may be formed of a conductive material, such as titanium, or of a combination of conductive and non-conductive materials. The conductive material of the housing functions as a housing electrode. ICD 14 may also include a connector assembly (also referred to as a connector block or header) that includes electrical feedthroughs through which electrical connections are made between lead 16 and electronic components included within the housing. The housing may house one or more processors, memories, transmitters, receivers, sensors, sensing circuitry, therapy circuitry, power sources and other appropriate components.
ICD 14 is configured to be implanted in a patient, such as patient 12. ICD 14 is on the left side of patient 12 above the ribcage. ICD 14 may, in some instances, be implanted between the left posterior axillary line and the left anterior axillary line of patient 12. ICD 14 may, however, be implanted at other subcutaneous locations on patient 12 such as at a pectoral location or abdominal location.
Lead 16 includes an elongated lead body having a proximal end that includes a connector (not shown) configured to be connected to ICD 14 and a distal portion that includes electrodes 24, 28, and 30. The implant tools and techniques of this disclosure may be used to implant lead 16 (or other type of lead or device) as described herein. Lead 16 extends subcutaneously above the ribcage from ICD 14 toward a center of the torso of patient 12, e.g., toward xiphoid process 20 of patient 12. At a location near the center of the torso, lead 16 bends or turns and extends superior under/below sternum 22 within anterior mediastinum 36. Anterior mediastinum 36 may be viewed as being bounded laterally by pleurae 39, posteriorly by pericardium 38, and anteriorly by sternum 22. In some instances, the anterior wall of anterior mediastinum 36 may also be formed by the transversus thoracis and one or more costal cartilages. Anterior mediastinum 36 includes a quantity of loose connective tissue (such as areolar tissue), some lymph vessels, lymph glands, substernal musculature (e.g., transverse thoracic muscle), branches of the internal thoracic artery, and the internal thoracic vein. In one example, the distal portion of lead 16 may be implanted substantially within the loose connective tissue and/or substernal musculature of anterior mediastinum 36.
In other embodiments, the distal portion of lead 16 may be implanted in other non-vascular, extra-pericardial locations, including the gap, tissue, or other anatomical features around the perimeter of and adjacent to, but not attached to, the pericardium or other portion of heart 26 and not above sternum 22 or ribcage. As such, lead 16 may be implanted anywhere within the “substernal space” defined by the undersurface between the sternum and/or ribcage and the body cavity but not including the pericardium or other portion of heart 26. The substernal space may alternatively be referred to by the terms “retrosternal space” or “mediastinum” or “infrasternal” as is known to those skilled in the art and includes the anterior mediastinum 36. The substernal space may also include the anatomical region described in Baudoin, Y. P., et al., entitled “The superior epigastric artery does not pass through Larrey's space (trigonum sternocostale).” Surg.Radiol.Anat. 25.3-4 (2003): 259-62. In other words, the distal portion of lead 16 may be implanted in the region around the outer surface of heart 26, but not attached to heart 26.
The distal portion of lead 16 may be implanted substantially within anterior mediastinum 36 such that electrodes 24, 28, and 30 are located near a ventricle of heart 26. For instance, lead 16 may be implanted within anterior mediastinum 36 such that electrode 24 is located over a cardiac silhouette of one or both ventricles as observed via an anterior-posterior (AP) fluoroscopic view of heart 26. In one example, lead 16 may be implanted such that a therapy vector from electrode 24 to a housing electrode of ICD 14 is substantially across the ventricles of heart 26. The therapy vector may be viewed as a line that extends from a point on electrode 24, e.g., center of electrode 24, to a point on the housing electrode of ICD 14, e.g., center of the housing electrode. However, lead 16 may be positioned at other locations as long as the therapy vector between electrode 24 and the housing electrode is capable of defibrillating heart 26.
In the example illustrated in
In the example illustrated in
Implant tool 50 includes a handle 52 and an elongate shaft 54 adjacent to handle 52. Shaft 54 defines an open channel 56 that extends from handle 52 to a distal end 58. Open channel 56 may extend the entire length of shaft 54 from handle 52 to distal end 58. Shaft 24 has a length, labeled “L1” in
Shaft 54 may have a relatively uniform thickness along the longitudinal length of shaft 54, e.g., along major axis “X” defined by implant tool 50. Alternatively, the thickness of the walls of shaft 54 may not be uniform along the length of shaft 54. For example, the walls of shaft 54 may have an increased thickness toward distal end 58 compared to the proximal end of shaft 54. The increased thickness toward distal end 58 may enable improved tunneling performance by increasing rigidness or stiffness at distal end 58 or by reducing interference with the tissue. Additionally, the increased thickness of distal end 58 may aid in shaping distal end to avoid coring, cutting, or puncturing of tissue, pleura, pericardium or other parts of patient 12. In other instances, distal end 58 and the proximal end near handle 52 of shaft 54 may have a greater thickness compared to the middle portion of shaft 54.
As illustrated in the cross sectional view of distal end 58 of shaft 54 (
Open channel 56 has a depth, labeled “D” in
Open channel 56 also includes a width, labeled “W1” in
Shaft 54 may have the same cross section along the entire length of shaft 54. Alternatively, shaft 54 may have varying cross sections along portions of the length of shaft 54. For example, may have a more open cross-section, e.g., a U-shaped cross-section toward a proximal end of shaft 54 and a C-shaped cross-section along the mid and distal sections of the shaft 54. Other varying cross-sections may be utilized without departing from the scope of this disclosure. Shaft 54 may have a total cross-sectional thickness (T) of between approximately 0.080-0.450 inches and a total width (W2) of approximately 0.080-0.450 inches.
In the examples described above, implant tool 50 may be to be used to implant a particular sized lead such that a different implant tool (e.g., having a different sized open channel 56) may be selected depending on the size of the lead to be implanted, which may range from 2 French to 11 French. In further examples, a single implant tool 50 may be designed to deliver leads having a variety of different diameters. In this case, the depth D and width W of open channel 56 may be sized for delivery of the largest diameter lead for which tool 50 is designed.
Shaft 54 may have a relatively uniform thickness along the sides and bottom of the body of shaft 54. In other words, the walls along the sides and bottom of shaft 54 may all have about the same thickness. In another example, however, shaft 54 may have thicker walls along the sides of shaft 54 forming open channel 56 than along the bottom of shaft 54.
Shaft 54 also includes a lumen 59 that extends from the proximal end connected to the handle 52 to a location near the distal end 58. Lumen 59 may be used to deliver fluid from a syringe or other fluid delivery device located near or within handle 52. In one example, handle 52 may include a coupler, such as a Luer fitting, that couples with a syringe or other fluid delivery device. The operator of tool 50 may inject fluid via lumen 59 for any of a number of purposes, including but not limited to pain reduction during and post tunneling, addition of fluids to minimize air around the lead electrodes during acute testing and/or for electrical noise reductions, for flushing out the subcutaneous and/or substernal tunnel formed by implant tool 30, and/or for the placement of antimicrobials agents to reduce infection potential. Lumen 59 may have any of a number of diameters depending upon the intended use of lumen 59.
Lumen 59 may be sized for use in other contexts in addition to or instead of delivery of fluid. For example, lumen 59 may be sized to receive a guide wire, a needle, or other structure that may be extended and retracted during tunneling of tool 50. In this manner, the operator may utilize the guide wire, needle or other structure to traverse the diaphragmatic attachments and/or any tissue, muscle, ligaments, or other structures in the tunneling path. In the case of a needle, for example, the user may extend the needle out the distal end of lumen 59 to pass through the diaphragmatic attachments and then retract the needle to continue tunnel with the blunt portion of shaft 54. In other examples, a radiopaque tube/rod can be placed in lumen 59 to provide radio-opacity to a polymer tunneling tool, an electrical probe can be positioned in lumen 59 to monitor electrical signals of the heart to provide impedance measurements of surrounding tissue, and/or lumen can be used to house a fiberscope for direct visualization.
In some instances, shaft 54 may include more than one lumen 59 extending down the length of shaft 54. For example, a first lumen may be used to provide fluids and the second lumen may be used for the guide wire, needle or other component. Although illustrated as being along a bottom of tool 50, lumen(s) 59 may be at other locations within the body of shaft 54, e.g., along one or both of the side walls. Lumen 59 is illustrated as having a circular cross-section, but lumen 59 may have different cross-sectional shapes. In one example, lumen 59 may be a shape similar to that of shaft 54 (e.g., C-shape, U-shape, or other arc shape). Lumen 59 may have an opening at the distal end of shaft 54 in one example (as illustrated in
Handle 52 may, in some instances, include a compartment or recess 53 (illustrated in
Elongate shaft 54 of implant tool 50 is formed such that it is stiff enough to be capable of being pushed through the tissue, muscle or other structure to form a path through the body. Shaft 54 may be made of a metal, polymer, or other material or combination of materials, e.g., metal, metal alloy, polymer, or a combination thereof. Handle 52 of implant tool 50 may also be made of a metal, alloy, polymer, or other material or combination of materials. Handle 52 and elongate shaft 54 may, in some instances, be constructed of the same material. For example, implant tool 50 may be formed of a single, unitary piece of material, such as metal or rigid polymer. In other instances, handle 52 and elongate shaft 54 may be constructed of different materials. In this case, handle 52 and shaft 54 may be formed of separate components that are attached together to form implant tool 50, e.g., via a two piece construction. For example, handle 52 may be made of polymer and shaft 54 may be made of metal and attached to handle 52 to form implant tool 50. Example metals or metal alloys from which handle 52 or shaft 54 may be constructed include, but are not limited to, stainless steel, titanium, titanium alloys, nickel-cobalt, and nickel-cobalt alloys. Example polymers may include, but are not limited to, acetal resin (e.g., DELRIN®), polyether ether ketone (PEEK), polycarbonate, polypropylene composites, and liquid-crystal polymer (LCP). In addition, lubricious fillers and coatings may be used to improve lubricity during tunneling and lead insertion. Such additives or coatings include, but are not limited to, siloxane, PTFE, and Foster ProPell™. Example radiopaque additives may include, without limitation, BaSO4, WC, and Bi2O3.
Distal end 58 of shaft 54 may be shaped to aid in tunneling through tissue or muscle. For example, distal end 58 of the shaft 54 may be tapered, angled, blunt, rounded, pointed, bent or otherwise shaped to enable a user to tunnel through subcutaneous tissue without excess damage to surrounding tissue, piercing through the skin, or coring of the tissue.
A user of tool 50 may insert tool 50 into an incision and tunnel distal end 58 of shaft 54 to a desired location. Once at the desired location, the user may deliver an implantable electrical lead, such as defibrillation lead 16 of
Sheath 70 has a length (L2) that is less than the length (L1) of shaft 64 of implant tool 60. As such, when sheath 70 is placed over shaft 64 of implant tool 60, shaft 64 extends from the distal end of sheath 70. As illustrated best in
Sheath 70 includes a body 72 having a proximal end and a distal end. In some instances, the distal end of body 72 may be tapered to aid in tunneling. Body 72 of sheath 70 defines an inner channel 78. In the examples described herein, the cross-section of an outside of body 72 and the inner channel 78 defined by body 72 is substantially C-shaped. However, the cross-section of either the outside of body 72 and/or the inner channel 78 defined by body 72 may be a different shape depending on the desired application. The cross-section is taken normal (i.e., perpendicular) to the longitudinal length of sheath 70 from the distal end of body 72 to the proximal end of body 72.
Sheath 70 includes an opening 76 along the length of body 72. As described further herein, opening 76 along body 72 may form a gap between the ends of body 72 located at the boundary of the opening (as can be viewed in the cross-sectional view of sheath 70). Inner channel 78 is accessible via opening 76. Opening 76 extends the entire length of body 72 from the distal end to the proximal end. In other examples, opening 76 may not extend the entire length of the body 72. Inner channel 78 is accessible via opening 76. In the example illustrated in
Sheath 70 may be sized such that sheath 70 fits on shaft 64 of implant tool 60 in such a manner that an interference fit is achieved between sheath 70 and shaft 64. The interference fit is achieved by friction after the parts are pushed together, rather than by any other means of fastening. The interference fit may, in some instances, be achieved by sizing and/or shaping the two mating parts so that one or the other, or both, slightly deviate in size from the nominal dimension. The interference fit may therefore be viewed as referring to the fact that one part slightly interferes with the space that the other is taking up. The tightness of the interference fit may be controlled by the amount of allowance, e.g., the planned difference from nominal size. Different allowances will result in various strengths of fit. The value of the allowance depends on which material is being used, how big the parts are, and what degree of tightness is desired.
In one example, the diameter of the inner channel 78 formed by body 72 of sheath 70 may be equal to or slightly smaller than the outer diameter of shaft 64. The allowance in this case may be on the order of 1-10 thousandths of an inch. Allowances of less than 1 thousandth and greater than 10 thousands may be used, however. As such, when placed over shaft 64, sheath 70 slightly expands in diameter causing the interference fit. Other techniques for achieving an interference fit may also be utilized.
Sheath 70 may be formed to have a thickness 79 that may vary depending the type of material used to form sheath 70, the desired rigidity of sheath 70, or the like. Sheath 70 should be rigid enough to not crumple, wrinkle, crease, or crush while being tunneled through tissue of patient 12. Sheath 70 may be made of extruded or molded material. The material may include, but not limited to, a polymer, a copolymer, a thermoplastic, or other material. Example materials include, but are not limited to, polyether block amide (such as PEBAX® 72D), polyether block amide blends (PEBAX® with a Foster ProPell™ additive), polyethylene, ultra-high-molecular-weight polyethylene (UHMWPE), Polytetrafluoroethylene (PTFE), nylons (such as GRILAMID® TR55 or L25, VESTAMID® L2140, AESNO®), or the like. In some instances, sheath 70 may be made of multiple layers of different materials or may vary in materiality and durometer along the length of body 72. For example, sheath 70 may be formed of PEBAX® with a PTFE lining the inner surface of the channel. Other additives or coatings that may be applied to increase lubricity include, but are not limited to, siloxane, PTFE, and Foster ProPell™
Opening 76 may vary in size depending upon the desired application. Opening 76 may be less than the diameter of lead 16. In one example, opening 76 may be approximately 10% less than the diameter of lead 16. However, in other examples, opening 76 may be less than 10% of the diameter of lead 16 or more than 10% of the diameter of lead 16. Opening 76 may be larger or smaller than illustrated in
The implant tools and/or systems described herein may be used to implant medical leads, catheters, or other implantable component. In one example, the implant tools and/or systems described herein may be used to implant a medical electrical lead at least partially within the substernal space, e.g., within anterior mediastinum of patient 12. Alternatively or additionally, the implant tools and/or systems described herein may be used to implant a medical electrical lead along subcutaneous paths above the ribcage/sternum.
In one example, implant tool 50 (or other tool described herein) is introduced into an incision near the center of the torso of patient 12. Implant tool 50 is advanced from the incision superior along the sternum either substernally or subcutaneously. The distal end of lead 16 (or other lead, catheter or implantable component) is introduced into open channel 56 of shaft 54 near the incision. The distal end of lead 16 is advanced along open channel 56 from the incision toward distal end 58 of shaft 54. Implant tool 50 is withdrawn toward the incision and removed from the body of patient 12 while leaving defibrillation lead 16 in place along the path along the sternum.
Implant tool 50 may be used to form a subcutaneous tunnel lateral between the center of the torso of the patient to a pocket on the left side of the patient. Lead 16 may be advance along channel 56 and implant tool 50 may be removed leaving the proximal portion of lead 16 in place along the lateral path. This may be done before or after implanting the distal portion of lead 16.
During the implantation, the operator of tool 50 (or other tool described herein) may inject fluid via lumen 59 for any of a number of purposes, including but not limited to pain reduction during and post tunneling, addition of fluids to minimize air around the lead electrodes during acute testing and/or for electrical noise reductions, for flushing out the subcutaneous and/or substernal tunnel formed by implant tool 30, and/or for the placement of antimicrobials agents to reduce infection potential.
Various examples have been described. However, the exampled described herein should not be limiting of the contents of this disclosure. In other examples, the open channel tool may not include a lumen or a second open channel for receiving a tube. Instead, a sheath may be used in conjunction with the open channel tool and the sheath may include a lumen built into the sheath. In another example, a tubular fluid lumen is placed directly into the main channel during tunneling. To aid it staying in position during tunneling the tubing incorporates clip/marker feature to assure tubing remains in place during tunneling. The lumen can also be formed with a shape similar to shaft to help hold the sheath in place before and during tunneling. With this embodiment, fluid can be administered during tunneling and prior to lead introductions.
These and other examples are within the scope of the following claims.
Number | Name | Date | Kind |
---|---|---|---|
4030509 | Heilman et al. | Jun 1977 | A |
4146037 | Flynn et al. | Mar 1979 | A |
4207903 | O'neill | Jun 1980 | A |
4270549 | Heilman | Jun 1981 | A |
4280510 | O'Neill | Jul 1981 | A |
4291707 | Heilman et al. | Sep 1981 | A |
4424818 | Doring et al. | Jan 1984 | A |
4437475 | White | Mar 1984 | A |
4512351 | Pohndorf | Apr 1985 | A |
4538624 | Tarjan | Sep 1985 | A |
4644957 | Ricciardelli et al. | Feb 1987 | A |
4765341 | Mower et al. | Aug 1988 | A |
4832687 | Smith, III | May 1989 | A |
4921479 | Grayzel | May 1990 | A |
5009643 | Reich et al. | Apr 1991 | A |
5036854 | Schollmeyer et al. | Aug 1991 | A |
5125904 | Lee | Jun 1992 | A |
5147376 | Pianetti | Sep 1992 | A |
5176135 | Fain et al. | Jan 1993 | A |
5255691 | Otten | Oct 1993 | A |
5257973 | Villasuso | Nov 1993 | A |
5258003 | Ciaglia et al. | Nov 1993 | A |
5300106 | Dahl et al. | Apr 1994 | A |
5312355 | Lee | May 1994 | A |
5346502 | Estabrook et al. | Sep 1994 | A |
5364372 | Danks et al. | Nov 1994 | A |
5441504 | Pohndorf et al. | Aug 1995 | A |
5456699 | Armstrong | Oct 1995 | A |
5478329 | Ternamian | Dec 1995 | A |
5509924 | Paspa et al. | Apr 1996 | A |
5613953 | Pohndorf | Mar 1997 | A |
5667514 | Heller | Sep 1997 | A |
5671736 | Pettit et al. | Sep 1997 | A |
5690648 | Fogarty et al. | Nov 1997 | A |
5752937 | Otten et al. | May 1998 | A |
5755697 | Jones et al. | May 1998 | A |
5779715 | Tu | Jul 1998 | A |
5782841 | Ritz et al. | Jul 1998 | A |
5800398 | Hahnle et al. | Sep 1998 | A |
5853391 | Bell | Dec 1998 | A |
5871528 | Camps et al. | Feb 1999 | A |
5871532 | Schroeppel | Feb 1999 | A |
5944732 | Raulerson et al. | Aug 1999 | A |
5951518 | Licata et al. | Sep 1999 | A |
6032079 | KenKnight et al. | Feb 2000 | A |
6104957 | Alo et al. | Aug 2000 | A |
6122552 | Tockman et al. | Sep 2000 | A |
6159198 | Gardeski et al. | Dec 2000 | A |
6228052 | Pohndorf | May 2001 | B1 |
6278897 | Rutten et al. | Aug 2001 | B1 |
6283948 | McKernan et al. | Sep 2001 | B1 |
6324414 | Gibbons et al. | Nov 2001 | B1 |
6415187 | Kuzma et al. | Jul 2002 | B1 |
6436068 | Bardy | Aug 2002 | B1 |
6445954 | Olive et al. | Sep 2002 | B1 |
6544247 | Gardeski et al. | Apr 2003 | B1 |
6605094 | Mann et al. | Aug 2003 | B1 |
6726617 | Schmidt | Apr 2004 | B1 |
6730083 | Freigang et al. | May 2004 | B2 |
6733500 | Kelley et al. | May 2004 | B2 |
6749574 | O'Keefe | Jun 2004 | B2 |
6770070 | Balbierz | Aug 2004 | B1 |
6772014 | Coe et al. | Aug 2004 | B2 |
6836687 | Kelley et al. | Dec 2004 | B2 |
6866044 | Bardy et al. | Mar 2005 | B2 |
6868291 | Bonner et al. | Mar 2005 | B1 |
6887229 | Kurth | May 2005 | B1 |
7001396 | Glazier et al. | Feb 2006 | B2 |
7018384 | Skakoon | Mar 2006 | B2 |
7033326 | Pianca et al. | Apr 2006 | B1 |
7069083 | Finch et al. | Jun 2006 | B2 |
7076296 | Rissmann et al. | Jul 2006 | B2 |
7117039 | Manning et al. | Oct 2006 | B2 |
7151965 | Osypka | Dec 2006 | B2 |
7194309 | Ostroff et al. | Mar 2007 | B2 |
7195637 | Mika | Mar 2007 | B2 |
7218970 | Ley et al. | May 2007 | B2 |
7229450 | Chitre et al. | Jun 2007 | B1 |
7288096 | Chin | Oct 2007 | B2 |
7316667 | Lindstrom et al. | Jan 2008 | B2 |
7322960 | Yamamoto et al. | Jan 2008 | B2 |
7361169 | Reilly | Apr 2008 | B2 |
7369899 | Malinowski et al. | May 2008 | B2 |
7389134 | Karicherla et al. | Jun 2008 | B1 |
7450997 | Pianca et al. | Nov 2008 | B1 |
7499758 | Cates et al. | Mar 2009 | B2 |
7499759 | Coe et al. | Mar 2009 | B2 |
7539542 | Malinowski | May 2009 | B1 |
7627375 | Bardy et al. | Dec 2009 | B2 |
7655014 | Ko et al. | Feb 2010 | B2 |
7736309 | Miller et al. | Jun 2010 | B2 |
7736330 | Bardy | Jun 2010 | B2 |
7758590 | Daniele et al. | Jul 2010 | B2 |
7765014 | Eversull et al. | Jul 2010 | B2 |
7837671 | Eversull et al. | Nov 2010 | B2 |
7846088 | Ness | Dec 2010 | B2 |
7890191 | Rutten et al. | Feb 2011 | B2 |
7930040 | Kelsch et al. | Apr 2011 | B1 |
7983765 | Doan et al. | Jul 2011 | B1 |
8012127 | Lieberman et al. | Sep 2011 | B2 |
8057486 | Hansen | Nov 2011 | B2 |
8060207 | Wallace et al. | Nov 2011 | B2 |
8065020 | Ley et al. | Nov 2011 | B2 |
8066702 | Rittman, III et al. | Nov 2011 | B2 |
8090451 | Tyson, Jr. | Jan 2012 | B2 |
8155755 | Flynn et al. | Apr 2012 | B2 |
8157813 | Ko et al. | Apr 2012 | B2 |
8260436 | Gerber et al. | Sep 2012 | B2 |
8271094 | Moffitt et al. | Sep 2012 | B1 |
8280527 | Eckerdal et al. | Oct 2012 | B2 |
8340779 | Harris et al. | Dec 2012 | B2 |
8340781 | Konishi | Dec 2012 | B2 |
8355786 | Malinowski | Jan 2013 | B2 |
8364277 | Glukhovsky | Jan 2013 | B2 |
8386052 | Harris et al. | Feb 2013 | B2 |
8409233 | Chinn et al. | Apr 2013 | B1 |
8435208 | Bardy | May 2013 | B2 |
8442620 | Silipo et al. | May 2013 | B2 |
8447396 | Palti et al. | May 2013 | B2 |
8447398 | Bardy et al. | May 2013 | B2 |
8452421 | Thenuwara et al. | May 2013 | B2 |
8454552 | Bardy | Jun 2013 | B2 |
8478424 | Tronnes | Jul 2013 | B2 |
8478426 | Barker | Jul 2013 | B2 |
8942820 | Doerr et al. | Jan 2015 | B2 |
9227053 | Bonde et al. | Jan 2016 | B2 |
20020120277 | Hauschild et al. | Aug 2002 | A1 |
20020120294 | Kroll | Aug 2002 | A1 |
20020143251 | Richardson et al. | Oct 2002 | A1 |
20030114908 | Flach | Jun 2003 | A1 |
20030233115 | Eversull et al. | Dec 2003 | A1 |
20040054388 | Osypka | Mar 2004 | A1 |
20040059348 | Geske et al. | Mar 2004 | A1 |
20040064147 | Struble | Apr 2004 | A1 |
20040102829 | Bonner et al. | May 2004 | A1 |
20040176781 | Lindstrom et al. | Sep 2004 | A1 |
20040210293 | Bardy et al. | Oct 2004 | A1 |
20040236396 | Coe et al. | Nov 2004 | A1 |
20050049663 | Harris et al. | Mar 2005 | A1 |
20050119680 | Dykes | Jun 2005 | A1 |
20050131505 | Yokoyama | Jun 2005 | A1 |
20050288758 | Jones et al. | Dec 2005 | A1 |
20060041295 | Okypka | Feb 2006 | A1 |
20060116746 | Chin | Jun 2006 | A1 |
20060122676 | Ko et al. | Jun 2006 | A1 |
20060155250 | Endo et al. | Jul 2006 | A1 |
20060253181 | Schulman et al. | Nov 2006 | A1 |
20060265047 | Dorn | Nov 2006 | A1 |
20070066977 | Assell et al. | Mar 2007 | A1 |
20070083217 | Eversull | Apr 2007 | A1 |
20070100409 | Worley et al. | May 2007 | A1 |
20070173900 | Siegel et al. | Jul 2007 | A1 |
20070203553 | Smits | Aug 2007 | A1 |
20070208402 | Helland et al. | Sep 2007 | A1 |
20070249992 | Bardy | Oct 2007 | A1 |
20080046056 | O'Connor | Feb 2008 | A1 |
20080097424 | Wizeman et al. | Apr 2008 | A1 |
20080103572 | Gerber | May 2008 | A1 |
20080132933 | Gerber | Jun 2008 | A1 |
20080132970 | Barolat | Jun 2008 | A1 |
20080167650 | Joshi et al. | Jul 2008 | A1 |
20080234717 | Bruszewski | Sep 2008 | A1 |
20080243219 | Malinowski et al. | Oct 2008 | A1 |
20080269716 | Bonde et al. | Oct 2008 | A1 |
20080269763 | Bonde et al. | Oct 2008 | A1 |
20090018603 | Mitelberg et al. | Jan 2009 | A1 |
20090043373 | Arnault De La Menardiere et al. | Feb 2009 | A1 |
20090069750 | Schraga | Mar 2009 | A1 |
20090076521 | Hansen | Mar 2009 | A1 |
20090157091 | Buysman | Jun 2009 | A1 |
20090222021 | Chang | Sep 2009 | A1 |
20090259283 | Brandt et al. | Oct 2009 | A1 |
20090264780 | Schilling | Oct 2009 | A1 |
20100016935 | Strandberg et al. | Jan 2010 | A1 |
20100030227 | Kast et al. | Feb 2010 | A1 |
20100030228 | Havel | Feb 2010 | A1 |
20100056858 | Mokelke et al. | Mar 2010 | A1 |
20100094252 | Wengreen et al. | Apr 2010 | A1 |
20100113963 | Smits et al. | May 2010 | A1 |
20100125194 | Bonner et al. | May 2010 | A1 |
20100137879 | Ko et al. | Jun 2010 | A1 |
20100152747 | Padiy et al. | Jun 2010 | A1 |
20100198229 | Olomutzki | Aug 2010 | A1 |
20100217298 | Bardy | Aug 2010 | A1 |
20100217301 | Bardy | Aug 2010 | A1 |
20100249696 | Bardy | Sep 2010 | A1 |
20100268024 | Brannon | Oct 2010 | A1 |
20100305428 | Bonner et al. | Dec 2010 | A1 |
20100318098 | Lund et al. | Dec 2010 | A1 |
20110009877 | Thenuwara et al. | Jan 2011 | A1 |
20110009933 | Barker | Jan 2011 | A1 |
20110022057 | Eigler et al. | Jan 2011 | A1 |
20110224680 | Barker | Sep 2011 | A1 |
20110224681 | McDonald | Sep 2011 | A1 |
20110257660 | Jones et al. | Oct 2011 | A1 |
20120016377 | Geroy | Jan 2012 | A1 |
20120029335 | Sudam et al. | Feb 2012 | A1 |
20120078266 | Tyson, Jr. | Mar 2012 | A1 |
20120089153 | Christopherson et al. | Apr 2012 | A1 |
20120097174 | Spotnitz et al. | Apr 2012 | A1 |
20120191106 | Ko et al. | Jul 2012 | A1 |
20120209283 | Zhu | Aug 2012 | A1 |
20120209285 | Barker et al. | Aug 2012 | A1 |
20120290057 | Boling et al. | Nov 2012 | A1 |
20130103049 | Bonde | Apr 2013 | A1 |
20130110159 | Litvack et al. | May 2013 | A1 |
20130158564 | Harris et al. | Jun 2013 | A1 |
20130238067 | Baudino | Sep 2013 | A1 |
20130253260 | Lund | Sep 2013 | A1 |
20130296879 | Lazeroms et al. | Nov 2013 | A1 |
20130317583 | Pianca | Nov 2013 | A1 |
20140012292 | Stewart et al. | Jan 2014 | A1 |
20140039264 | Heiman | Feb 2014 | A1 |
20140073926 | Rajendran | Mar 2014 | A1 |
20140148786 | Milo | May 2014 | A1 |
20140163655 | Chitre et al. | Jun 2014 | A1 |
20140276927 | Barker | Sep 2014 | A1 |
20140330208 | Christie et al. | Nov 2014 | A1 |
20140336581 | Collin | Nov 2014 | A1 |
20150032142 | Silvestro | Jan 2015 | A1 |
20150105793 | Cole | Apr 2015 | A1 |
20150133951 | Seifert et al. | May 2015 | A1 |
20150133952 | Seifert et al. | May 2015 | A1 |
20150133953 | Seifert et al. | May 2015 | A1 |
20150133954 | Seifert et al. | May 2015 | A1 |
20150216519 | Tang et al. | Aug 2015 | A1 |
20150313633 | Gross | Nov 2015 | A1 |
20160157890 | Drake et al. | Jun 2016 | A1 |
20160158530 | Drake et al. | Jun 2016 | A1 |
Number | Date | Country |
---|---|---|
2364868 | Feb 2000 | CN |
101502699 | Aug 2009 | CN |
102202726 | Sep 2011 | CN |
103157181 | Jun 2013 | CN |
0517494 | Sep 1992 | EP |
9720530 | Jun 1997 | WO |
2001023035 | Apr 2001 | WO |
2004073506 | Sep 2004 | WO |
2010045228 | Apr 2010 | WO |
2013076213 | May 2013 | WO |
Entry |
---|
Obadia, et al., “New Approach for Implantation of Automatic Defibrillators Using Videothoracoscopy”, Journal Ann Cardiol Angeiol (Paris); Sep. 1994; 43 (7) Abstract Only, 1 page. |
Lemmer, “Defibrillator Patch Constriction, Letter to the Editor”, The Annals of Thoracic Surgery, 1996, 1 page. |
Ely et al., “Thoracoscopic Implantation of the Implantable Cardioverter Defibrillator”, Minimally Invasive Techniques; (Can be found on the World-Wide Web at http://chestioumal.chestpubs.org on May 6, 2013); dated Jan. 1993; 2 pages. |
Damiano, “Implantation of Cardioverter Defibrillators in the Post-Sternotomy Patient”, The Annals of Thoracic Surgery, 1992; 53: pp. 978-983. |
Piccione, et al., “Erosion of Extrapericardial Implantable Cardioverter Defibrillator Patch Through the Gastic Fundus with Fistulous Tract Information”, Cardiology in Review; 2006; 14, e21-e23 pages. |
Vyhmeister et al., “Simple Approach for Extrapericardial Placement of Defibrillator Patches via Median Sternotomy”, The Annals of Thoracic Surgery; 1994; 57: 4 pages. |
Harman et al., “Differences in the Pathological Changes in Dogs' Hearts After Defibrillation with Extrapericardial Paddles and Implanted Defibrillator Electrodes”, Journal of Pacing and Clinical Electrophysiology, Feb. 1991; vol. 14; Part 2; 5 pages. |
Obadia et al., “Thoracoscopic Approach to Implantable Cardioverter Defibrillator Patch Electrode Implantation”, Pacing and Clinical Electrophysiology; Jun. 1996; vol. 19; 6 pages. |
Shapira, et al., A Simplied Method for Implantation of Automatic Cardioverter Defibrillator in Patients with Previous Cardiac Surgery, Pacing and Clinical Electrophysiology, January Part I, 1993, vol. 16; 6 pages. |
Quigley et al., “Migration of an Automatic Implantable Cardioverter-Defibrillator Patch Causing Massive Hemothorax”, Journal Texas Heart Institute, Nov. 1, 1996; vol. 23, 4 pages. |
Karwande et al., Bilateral Anterior Thoracotomy for Automatic Implantable Cardioverter Defibrillator Placement in Patients with Previous Stemotomy, The Annals of Thoracic Surgery; Oct. 1992; 54(4); 3 pages. |
Bielefeld et al., “Thoracoscopic Placement of Implantable Cardioverter-Defibrillator Patch Leads in Sheep”, Circulation; Nov. 1993, vol. 88, No. 5, Part 2; 5 pages. |
Frame et al., “Long-Term Stability of Defibrillation Thresholds with Intrapericardial Defibrillator Patches”, Pacing and Clinical Electrophysiology, Jan. 1993, Part II, vol. 16, 6 pages. |
Lawrie et al., “Right Mini-Thoracotomy: An Adjunct to Left Subcostal Automatic Implantable Cardioverter Defibrillator Implantation”, The Annals of Thoracic Surgery; 1989; 47; 4 pages. |
Mitchell et al., “Experience with an Implantable Tiered Therapy Device Incorporating Antitachycardia Pacing and Cardioverter/Defibrillator Therapy”, Thoracic and Cardiovascular Surgery, Abstract Only, Mar. 1993, 1 page. |
Bolling et al., “Automatic Internal Cardioverter Defibrillator: A Bridge to Heart Transplantation”, Heart Lung Transplantation, Abstract Only, Jul.-Aug. 1991, 1 page. |
Steinke et al., Subepicardial Infarction, Myocardial Impression, and Ventricular Penetration by Sutureless Electrode and Leads, Chest; 70: Jul. 1, 1976, 2 pages. |
Avogadros Lab Supply Inc., Catalog; Scoopula with Beech Wood Handle, can be found on-line at http://www.avogadro-lab-supply.com/search.php, accessed Oct. 6, 2013, 1 page. |
Medtronic, Inc. 6996SQ Subcutaneous, Unipolar Lead with Defibrillation Coil Electrode, Technicial Manual, 22 pages. |
Medtronic, Inc. 6996T Tunneling Tool, Technical Manual, 12 pages. |
Pebax Product Brochure, 14 pages and can be found on-line at http://www.pebax.com/export/sites/pebax/.content/medias/downloads/literature/pebax-product-range-brochure.pdf, 14 pages. |
Cigna et al., A New Technique for Substemal Colon Transposition with a Breast Dissector: Report of 39 Cases, Journal of Plastic, Reconstructive and Aesthetic Surgery, 2006:59, 4 pages. |
Tung et al., “Minimal Invasive Extra Cardiac Placement of High Voltage Defibrillator Leads”, Poster 3; S200 Abstract, PO-3-4; St. Paul Hospital, Vancouver, British Columbia, Canada, 1 page. |
Molina et al, “An Epicardial Subxiphoid Implantable Defibrillator Lead: Superior Effectiveness After Failure of Stndard Implants”, From the Department of Surgery, Division of Cardiovascular and Thoracic Surgery and the Department of Medicine, Cardiac Arrhymthmia Center, University of Minnesota Medical School, Minneapolis, Minnesota, Pace, vol. 27, Nov. 2004, 7 pages. |
Boston Scientific, Emblem S-ICD Subcutaneous Electrode Insertion Tool, Model 4711 User Manual, Feb. 1, 2015, accessed from https://web.archive.org/web/20151025171513/https://www.bostonscientific.com/manuals/manuals/landing-page/US-english.html, 28 pp. |
Greatbatch Medical, OptiSeal Valved Peelable Introducer Brochure, 2010, 2 pp. (Applicant points out, in accordance with MPEP 609.04(a), that the year of publication, 2010, is sufficiently earlier than the effective U.S. filing date Dec. 18, 2014, so that the particular month of publication is not in issue.). |
Prosecution History from U.S. Appl. No. 14/962,485, dated Jul. 13, 2017 through May 24, 2018, 52 pp. |
Prosecution History from U.S. Appl. No. 14/962,541, dated Feb. 7, 2018 through May 7, 2018, 17 pp. |
Prosecution History from U.S. Appl. No. 14/193,573, dated May 2, 2014 through Jul. 3, 2018, 185 pp. |
Prosecution History from U.S. Appl. No. 14193,634, dated May 2, 2014 through Jan. 31, 2019, 277 pp. |
Prosecution History from U.S. Appl. No. 14/196,443, dated Nov. 12, 2015 through Dec. 9, 2016, 84 pp. |
Prosecution History from U.S. Appl. No. 14/196,298, dated Jul. 16, 2015 through Jan. 8, 2019, 219 pp. |
Prosecution History from U.S. Appl. No. 14/962,485, dated Jun. 25, 2018 through Feb. 14, 2019, 66 pp. |
Prosecution History from U.S. Appl. No. 14/962,541, dated Aug. 6, 2018 through Nov. 6, 2018, 41 pp. |
Number | Date | Country | |
---|---|---|---|
20160175008 A1 | Jun 2016 | US |
Number | Date | Country | |
---|---|---|---|
62093507 | Dec 2014 | US |